Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has shared an announcement.
Pharmaron Beijing Co., Ltd. announced that its board of directors will convene on October 28, 2025, to review and approve the company’s third-quarter results for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on providing a variety of pharmaceutical services and products.
Average Trading Volume: 15,769,958
Technical Sentiment Signal: Hold
Current Market Cap: HK$60.6B
Learn more about 3759 stock on TipRanks’ Stock Analysis page.